SF1126

Modify Date: 2024-01-06 23:28:02

SF1126 Structure
SF1126 structure
Common Name SF1126
CAS Number 936487-67-1 Molecular Weight 912.89600
Density N/A Boiling Point N/A
Molecular Formula C41H52N8O16 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of SF1126


SF1126 is a clinically relevant pan and dual first-in-class PI3K/BRD4 inhibitor, has antitumor and anti-angiogenic activity. SF1126 is an RGDS-conjugated LY294002 prodrug, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment. SF1126 induces cell apoptosis[1].

 Names

Name Semafore(SF1126)

 SF1126 Biological Activity

Description SF1126 is a clinically relevant pan and dual first-in-class PI3K/BRD4 inhibitor, has antitumor and anti-angiogenic activity. SF1126 is an RGDS-conjugated LY294002 prodrug, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment. SF1126 induces cell apoptosis[1].
Related Catalog
Target

PI3K/BRD4[1]

In Vitro SF1126 (0-6 µM; 48 hours) inhibits Hep3B, HepG2, SK-Hep1, and Huh7 cells proliferation with IC50s of 5.05, 6.89, 3.14, and 2.14 µM, respectively[1]. SF1126 (1-10 µM; 24 hours) results in cell-cycle arrest with a proportional increase in G0-G1 and a decrease in the number of cells in the S-phase in Hep 3B, Hep G2, SK-Hep1, and Huh7 cells[1]. SF1126 (0.5-2.5 µM; pre-30 minutes) and sorafenib suggests that combined treatment of SF1126 and sorafenib blocks multiple key enzymes in PI3K/AKT/mTOR and Ras/Raf/MAPK pathway[1]. Cell Viability Assay[1] Cell Line: Hep3B, HepG2, SK-Hep1, and Huh7 cells Concentration: 0 µM; 1 µM; 2 µM; 3 µM; 4 µM; 5 µM; 6 µM Incubation Time: 48 hours Result: Resulted in an increased inhibition of HCC proliferation. Cell Cycle Analysis[1] Cell Line: Hep3B, HepG2, SK-Hep1, and Huh7 cells Concentration: 1 µM; 5 µM; 10 µM Incubation Time: 24 hours Result: Induced cell-cycle arrest. Western Blot Analysis[1] Cell Line: Hep3B, HepG2, SK-Hep1, and Huh7 cells Concentration: 0.5 µM and 2.5 µM Incubation Time: Pre-30 mins Result: Suppressed phosphorylation of AKT, p70S6K, 4EBP1, and ERK in all the cell lines together with sorafenib.
References

[1]. Garlich JR, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 1;68(1):206-15.

 Chemical & Physical Properties

Molecular Formula C41H52N8O16
Molecular Weight 912.89600
Exact Mass 912.35000
PSA 381.50000
LogP 0.07440
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.